Literature DB >> 33376104

Forever Starts Now: Effects of Glucose-Lowering Therapies on Acute Kidney Injury.

Sradha Kotwal1,2, Vlado Perkovic3,4.   

Abstract

Entities:  

Keywords:  acute kidney injury; diabetes; glucose; randomized controlled trials

Mesh：

Substances：

Year:  2020        PMID： 33376104      PMCID： PMC7792634          DOI： 10.2215/CJN.18141120

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

Review 1.  Acute kidney injury from SGLT2 inhibitors: potential mechanisms.

Authors:  Kai Hahn; A Ahsan Ejaz; Mehmet Kanbay; Miguel A Lanaspa; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2016-11-16       Impact factor: 28.314

2.  Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.

Authors:  A Perlman; S N Heyman; I Matok; J Stokar; M Muszkat; A Szalat
Journal:  Nutr Metab Cardiovasc Dis       Date:  2017-10-18       Impact factor: 4.222

Review 3.  Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.

Authors:  Steven G Coca; Swathi Singanamala; Chirag R Parikh
Journal:  Kidney Int       Date:  2011-11-23       Impact factor: 10.612

4.  Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.

Authors:  Huilin Tang; Dandan Li; Jingjing Zhang; Yufeng Li; Tiansheng Wang; Suodi Zhai; Yiqing Song
Journal:  Diabetes Obes Metab       Date:  2017-03-31       Impact factor: 6.577

5.  World incidence of AKI: a meta-analysis.

Authors:  Paweena Susantitaphong; Dinna N Cruz; Jorge Cerda; Maher Abulfaraj; Fahad Alqahtani; Ioannis Koulouridis; Bertrand L Jaber
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

6.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

7.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

8.  Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.

Authors:  Lakhmir S Chawla; Rinaldo Bellomo; Azra Bihorac; Stuart L Goldstein; Edward D Siew; Sean M Bagshaw; David Bittleman; Dinna Cruz; Zoltan Endre; Robert L Fitzgerald; Lui Forni; Sandra L Kane-Gill; Eric Hoste; Jay Koyner; Kathleen D Liu; Etienne Macedo; Ravindra Mehta; Patrick Murray; Mitra Nadim; Marlies Ostermann; Paul M Palevsky; Neesh Pannu; Mitchell Rosner; Ron Wald; Alexander Zarbock; Claudio Ronco; John A Kellum
Journal:  Nat Rev Nephrol       Date:  2017-02-27       Impact factor: 28.314

9.  Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.

Authors:  Min Zhao; Shusen Sun; Zhenguang Huang; Tiansheng Wang; Huilin Tang
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.